Health2047

The AMA is the firm’s anchor strategic partner, and the firm states explicitly that it leverages the AMA’s direct insight into how care is provided, consumed, and valued in the U.S. That relationship is designed to inform thesis development and deal origination, giving Health2047 a window into clinical-practice realities that generalist funds lack. UnitedHealth Group’s presence as a strategic investor adds a payer-operations lens to the same process.

Managing Partner Douglass Given leads investment decisions. Given spent more than two decades as a partner and general partner at life-sciences investor Bay City Capital before joining Health2047. He is supported by Partners Rich Langdale, Gary Cookhorn, and Ray Bingham, who bring venture-investing, financial-operations, and technology-governance experience to the partnership.

It operates as an investment manager running a fund — Fund I — with the explicit goal of investing in companies pursuing system-level change in U.S. healthcare. The parent innovation studio, Health2047 Inc., was founded in 2015 with AMA backing to create and spin out companies; the Capital Partners entity manages the investment fund. The two are related but distinct, with the investment firm drawing on the broader platform’s sector intelligence.

The firm targets four broad areas: data liquidity, interoperability, and security; chronic-care delivery; radical productivity improvement through AI and machine learning; and new healthcare business models. It deploys capital into companies ranging from platform-level biosecurity (Carlyle One Health Group) to vaccinology (Vivaldi Biosciences), spanning early-stage to growth investments in the U.S., Europe, and China.

The firm does not publish a sector-exclusion list. Its public statements and portfolio point to a focus on system-level healthcare change, with no disclosed investments outside healthcare. There is no indication that it pursues therapeutics discovery, pure-play diagnostics, or fee-for-service care-delivery assets.

Health2047 Inc. is the AMA-backed innovation studio founded in 2015; Douglass Given served as its CEO from 2015 to 2018. Health2047 Capital Partners is the investment-management entity that runs Fund I, and it maintains close connections to the parent platform. The two share leadership ties — Given and Ray Bingham serve as directors of Health2047 Inc. — but the capital partnership is structured as a separate investment firm.

The firm does not publicly detail a co-investment program, but its limited-partner base includes UnitedHealth Group as a strategic investor, and LPs invest partly to collaborate on scalable solutions. The firm’s portfolio includes board-representation roles (Given is board chair of Vivaldi Biosciences and a board advisor to Carlyle One Health Group), suggesting active, often lead, participation in governance.